Hims & Hers Health (NYSE:HIMS) Earns Neutral Rating from Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of Hims & Hers Health (NYSE:HIMS) in a research report sent to investors on Friday, MarketBeat reports. The brokerage issued a neutral rating and a $32.00 price objective on the stock.

Several other equities analysts have also commented on the stock. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Bank of America upped their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Finally, Truist Financial boosted their target price on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $32.43.

Hims & Hers Health Price Performance

HIMS opened at $27.44 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The stock has a market capitalization of $6.40 billion, a P/E ratio of -43.56 and a beta of 2.42. The stock has a 50-day moving average price of $30.86 and a 200-day moving average price of $27.24. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $65.30.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s quarterly revenue was up 38.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.17 earnings per share. Equities analysts predict that Hims & Hers Health will post -0.1 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Patrick Carroll sold 23,726 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the transaction, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. This represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 16,773 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the sale, the insider owned 48,961 shares of the company’s stock, valued at $1,363,563.85. This trade represents a 25.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 190,227 shares of company stock worth $6,133,613. 11.76% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bienville Capital Management LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter valued at approximately $27,242,000. Engineers Gate Manager LP purchased a new stake in Hims & Hers Health in the second quarter worth $232,000. Integrated Wealth Concepts LLC bought a new position in Hims & Hers Health in the second quarter worth $147,000. Baird Financial Group Inc. raised its holdings in Hims & Hers Health by 384.6% in the second quarter. Baird Financial Group Inc. now owns 65,575 shares of the company’s stock worth $2,273,000 after purchasing an additional 52,043 shares in the last quarter. Finally, Nykredit A S purchased a new position in Hims & Hers Health during the second quarter valued at $222,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: JPMorgan initiates coverage with a $32 price target. JPMorgan Chase began coverage of Hims & Hers with a Neutral rating and a $32 target, implying potential upside from the reference price. The neutral stance suggests the firm sees some valuation support but wants greater clarity on the company’s outlook and risks. Benzinga coverage report
• Negative Sentiment: Multiple law firms publicized a securities class action against Hims & Hers. Kaplan Fox, Hagens Berman, Bronstein Gewirtz & Grossman, and other firms reminded investors that a lawsuit has been filed against the company and certain executives. The complaints generally allege that Hims & Hers made materially false or misleading statements or failed to disclose information related to its business practices, including alleged privacy-related conduct. The claims stem from the Federal Trade Commission’s federal complaint, which reportedly accuses the company of serious business misconduct. These allegations have not been proven in court. Hagens Berman class action announcement
• Negative Sentiment: The litigation creates continuing financial and reputational uncertainty. The proposed class covers investors who purchased Hims & Hers securities from August 4, 2025, through July 29, 2026. Investors have until November 2, 2026, to seek lead-plaintiff status. While the lawsuit itself does not establish liability, potential legal costs, damages, regulatory consequences, and customer trust concerns may pressure the shares and overshadow the company’s otherwise strong revenue growth. Kessler Topaz class action announcement

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.